An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension
Phase of Trial: Phase II/III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Tapentadol (Primary) ; Morphine
- Indications Pain
- Focus Therapeutic Use
- Sponsors Grunenthal
- 01 Aug 2019 Status changed from active, no longer recruiting to completed.
- 07 Feb 2019 This trial has been completed in UK (End date: 2018-10-15).
- 10 Jan 2019 This trial has been completed in Belgium (End date: 2018-10-15).